N. Jousset

Comparative efficacy of fingolimod vs natalizumab

P. Vermersch, S. Vukusic, B. Brochet, 2016, Neurology.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study

S. Vukusic, B. Brochet, D. Brassat, 2019 .

ngolimod vs natalizumab: A French multicenter observational study

S. Vukusic, B. Brochet, D. Brassat, 2016 .

Neuropathologic, phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis.

S. Nedellec, D. Laplaud, S. Brouard, 2016, Clinical immunology.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis

B. Brochet, G. Edan, D. Laplaud, 2020, Journal of Neurology.

Comparative efficacy of fingolimod vs natalizumab

P. Vermersch, S. Vukusic, B. Brochet, 2016, Neurology.